AVAH
Aveanna Healthcare Holdings Inc.
AVAH has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over AVAH overall, supported by stronger fundamentals.
AVAH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Under pressure |
AVAH's revenue, profitability and cash flow are currently healthy, but its balance sheet is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AVAH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.6x | $9.24 | -25% |
| Current | 8.7x | $12.24 | — |
| Forward | 14x | $12.24 | — |
| Fair | 21x | $29.51 | +141% |
| Expensive | 108x | $151 | +1130% |
Historical ranges are pointers, not guarantees.
AVAH's PE is in its cheap range at 8.7x. On analysts' estimates for next year's earnings, today's price would be 14x, in its fair range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AVAH in the historical PE scenario, which offers more potential upside but is not a forecast.
AVAH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AVAH, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over AVAH on the outlook, with more favorable valuation expectations.
AVAH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.88 | -37% |
| Q3 2026 | $1.40 | +278% |
| Q2 2026 | $1.26 | +1300% |
| Q1 2026 | $1.21 | +3933% |
| Q4 2025 | $1.05 | +$1.11 |
| Q3 2025 | $0.37 | +$0.71 |
| Q2 2025 | $0.09 | +$0.75 |
| Q1 2025 | $0.03 | +$0.63 |
| Q4 2024 | -$0.06 | +$0.65 |
AVAH has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AVAH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $695.5M | +12% |
| Q2 2026 | $670.5M | +14% |
| Q1 2026 | $647.9M | +16% |
| Q4 2025 | $662.5M | +27% |
| Q3 2025 | $621.9M | +22% |
| Q2 2025 | $589.6M | +17% |
| Q1 2025 | $559.2M | +14% |
| Q4 2024 | $519.9M | +8.6% |
AVAH's revenue has grown year over year for 19 quarters in a row: $696M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | +3.4 points |
| Q2 2026 | 12% | -1.7 points |
| Q1 2026 | 11% | +1.4 points |
| Q4 2025 | 11% | +1.9 points |
| Q3 2025 | 8.6% | +1.9 points |
| Q2 2025 | 14% | +6.2 points |
| Q1 2025 | 9.3% | +4.6 points |
| Q4 2024 | 8.8% | +2.7 points |
AVAH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AVAH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AVAH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $72.2M | +118% |
| Q2 2026 | $80.9M | +57% |
| Q1 2026 | $4.3M | +$13M |
| Q4 2025 | $49.7M | +271% |
| Q3 2025 | $33.2M | +13% |
| Q2 2025 | $51.6M | +2751% |
| Q1 2025 | -$8.6M | +$3.3M |
| Q4 2024 | $13.4M | +$16.4M |
AVAH has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
AVAH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +4.4M shares |
| 1 year | +3.1% | +7M shares |
| 3 years | +21% | +40.1M shares |
| 5 years | +29% | +51.5M shares |
| Available history | +27% | +49.1M shares |
AVAH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AVAH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.5x | Elevated |
| Q2 2026 | 4.2x | High |
| Q1 2026 | 3.9x | Elevated |
| Q4 2025 | 4.1x | High |
| Q3 2025 | 4.8x | High |
| Q2 2025 | 5.3x | High |
| Q1 2025 | 6.7x | High |
| Q4 2024 | 8.0x | High |
AVAH's net debt is about 3.5 years of its operating earnings (EBITDA), down from 4.8 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AVAH on leverage, with a lower net debt burden relative to earnings.
AVAH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 69.3 | Neutral |
AVAH's weekly RSI is 58 (neutral) and its Stochastic is 69 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AVAH PE vs Healthcare Sector
| Metric | AVAH | Sector median | Relative |
|---|---|---|---|
| PE | 8.7x | 26x | 66% below |
| PE % | 27 | 36 | 9 pts below |
AVAH has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AVAH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 3.6% below |
| 20 week MA | $11.9 | 2.6% above |
| 50 week MA | $9.34 | 31% above |
| 100 week MA | $7.66 | 60% above |
| 200 week MA | $5.12 | 139% above |
AVAH's trend is up, with a small recent dip: it's below only its 8-week average, and 139% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AVAH on trend strength, trading above more of its moving averages.
AVAH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $11.7 | $7.07 | -39% |
| 2022 | $7.07 | $0.77 | -89% |
| 2023 | $0.77 | $2.68 | +248% |
| 2024 | $2.68 | $4.66 | +74% |
| 2025 | $4.66 | $8.62 | +85% |
| 2026 YTD | $8.62 | $12.2 | +42% |
AVAH's yearly returns have swung widely, from +248% in 2023 to −89% in 2022. It's up 42% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AVAH on returns for 2026, with the stronger performance.